Newton vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI phone platform for dental practices handling patient scheduling, insurance verification, and reactivation campaigns; $3.8M seed from YC serving DSOs competing with Weave and NexHealth.
About
Newton is an AI-powered phone and patient communication platform for dental practices and dental service organizations (DSOs) — deploying AI voice agents that handle inbound patient calls (appointment scheduling, insurance verification questions, appointment reminders) and outbound patient reactivation campaigns that identify and contact overdue patients, automating the front-desk phone work that consumes significant staff time at dental offices. Founded in 2023 in San Francisco and a Y Combinator W24 graduate, Newton raised $3.8 million in seed funding in October 2025 from Y Combinator, Twenty Two Ventures, Transpose Platform, and Phosphor Capital.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.